For patients with the highest BRCA1 levels, the response rate was 58.6%, compared to 13.8% for those with intermediate levels and 27.6% for those with the lowest levels.[36] Based on these findings and those of the present study, the Spanish Lung Cancer Group is now modifying the protocol for a planned international phase III trial in advanced NSCLC to include customization based on RAP 80 as well as BRCA1 mRNA expression. Here, BRCA1 is linked to non-small cell lung carcinoma.